India Globalization Capital (NYSE American: IGC), in a historic first, has begun phase 2 clinical trials evaluating its flagship drug candidate, IGC-AD1, for the treatment of agitation in dementia from Alzheimer’s disease. “Company officials noted that, to their knowledge, this is the first natural low-dose THC-based compound to enter human trials for the treatment of symptoms such as agitation in dementia from Alzheimer’s disease. Currently there is no FDA-approved medication to treat agitation in Alzheimer’s,” reads a recent article. The piece quotes IGC CEO Ram Mukunda, who states, “We believe IGC-AD1 has the potential to revolutionize the treatment of the symptoms (agitation) of Alzheimer’s disease as the only natural low-dose THC-based formulation candidate currently undergoing FDA testing. Approximately 8 million people are affected by Alzheimer’s in North America and over 55 million worldwide. We believe that the diverse population we have selected for this study will allow us to accurately look at both the impact of variations of the gene CYP2C9 that metabolizes THC, as well as the APOE e4 a gene that increases the risk of developing Alzheimer’s. This data will help us to further understand the metabolism of IGC-AD1 for a diverse population, which is important in a disease that has a global impact like Alzheimer’s. Through these and further trials, we look forward to establishing IGC-AD1’s efficacy in treating the symptoms related to Alzheimer’s disease.”
To view the full article, visit https://ibn.fm/jX2lA
About India Globalization Capital Inc.
India Globalization Capital, through its subsidiary IGC Pharma LLC, develops advanced cannabinoid-based formulations for treating diseases, including but not limited to Alzheimer’s, Parkinson’s, chronic pain and pet seizures. The company’s leading drug candidate, IGC-AD1, has demonstrated, in Alzheimer’s cell lines, the potential to be effective in suppressing or ameliorating a key protein responsible for Aβ plaques and has recently entered phase 2 clinical trials for agitation in dementia from Alzheimer’s. The company, through its other subsidiary HH Processors, also has lines of various CBD-based consumer products such as Holief, which includes gummies and pain relief creams for women experiencing premenstrual syndrome (“PMS”) and dysmenorrhea (period cramps), and Sunday Seltzer, which includes a CBD-infused energy beverage – all currently available for purchase. The company, headquartered in Maryland, USA, also operates an infrastructure business based in India.
NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at https://ibn.fm/IGC
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
BioMedWire is part of the InvestorBrandNetwork.